Despite recent advances in the treatment of metastatic castration-resistant prostate cancer (mCRPC), agents that provide durable disease control and long-term survival are still needed. It is a fact that a tumor-induced immunosuppressive status (mediated by aberrant activation of inhibitory immune checkpoint pathways as a mechanism to evade host immune surveillance) plays a crucial role in the pathogenesis of cancer, including prostate cancer (PC), making CRPC patients suitable candidates for immunotherapy. Therefore, growing interest of anticancer research aims at blocking immune checkpoints (mainly targeting CTLA-4 and PD1/PD-L1 pathways) to restore and enhance cellular-mediated antitumor immunity and achieve durable tumor regression. In this review, we describe the current knowledge regarding the role of immune checkpoints in mediating PC progression, focusing on CTLA-4 and PD1 pathways. We also provide current clinical data available, an update on ongoing trials of immune checkpoint inhibitors in PC. Finally, we discuss the necessity to identify prognostic and predictive biomarkers of immune activity, and we analyze new immune checkpoints with a role as promising targets for PC therapy.

Modena, A., Ciccarese, C., Iacovelli, R., Brunelli, M., Montironi, R., Fiorentino, M., et al. (2016). Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?. ONCOLOGY REVIEWS, 10(1 Apr 15), 293-293 [10.4081/oncol.2016.293].

Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?

FIORENTINO, MICHELANGELO;Massari F.
2016

Abstract

Despite recent advances in the treatment of metastatic castration-resistant prostate cancer (mCRPC), agents that provide durable disease control and long-term survival are still needed. It is a fact that a tumor-induced immunosuppressive status (mediated by aberrant activation of inhibitory immune checkpoint pathways as a mechanism to evade host immune surveillance) plays a crucial role in the pathogenesis of cancer, including prostate cancer (PC), making CRPC patients suitable candidates for immunotherapy. Therefore, growing interest of anticancer research aims at blocking immune checkpoints (mainly targeting CTLA-4 and PD1/PD-L1 pathways) to restore and enhance cellular-mediated antitumor immunity and achieve durable tumor regression. In this review, we describe the current knowledge regarding the role of immune checkpoints in mediating PC progression, focusing on CTLA-4 and PD1 pathways. We also provide current clinical data available, an update on ongoing trials of immune checkpoint inhibitors in PC. Finally, we discuss the necessity to identify prognostic and predictive biomarkers of immune activity, and we analyze new immune checkpoints with a role as promising targets for PC therapy.
2016
Modena, A., Ciccarese, C., Iacovelli, R., Brunelli, M., Montironi, R., Fiorentino, M., et al. (2016). Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?. ONCOLOGY REVIEWS, 10(1 Apr 15), 293-293 [10.4081/oncol.2016.293].
Modena, A; Ciccarese, C; Iacovelli, R; Brunelli, M; Montironi, R; Fiorentino, Michelangelo; Tortora, G; Massari, F.
File in questo prodotto:
File Dimensione Formato  
onco-2016-1-293.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale (CCBYNC)
Dimensione 130.54 kB
Formato Adobe PDF
130.54 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/577799
Citazioni
  • ???jsp.display-item.citation.pmc??? 28
  • Scopus 57
  • ???jsp.display-item.citation.isi??? 49
social impact